T Lymphocytes and Anti-CD45 Monoclonal Antibody in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer - Related Studies

T Lymphocytes and Anti-CD45 Monoclonal Antibody in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer

This study is currently recruiting participants.

Study NCT00608257. Last updated on December 2, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Head and Neck Cancer

2	Additional conditions recognized in this trial
		Head and Neck Neoplasms
		Nasopharyngeal Neoplasms

3	More general conditions related to this trial
		Nasopharyngeal Diseases
		Neoplasms
		Neoplasms by Site
		Otorhinolaryngologic Diseases
		Otorhinolaryngologic Neoplasms
		Pharyngeal Diseases
		Pharyngeal Neoplasms
		Stomatognathic Diseases

4	Interventions listed in this trial
		anti-CD45 monoclonal antibody

5	Additional drug interventions recognized in this trial
		Antibodies
		Antibodies, Monoclonal

6	More general drug interventions related to this trial
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs

7	Sponsors listed in this trial
		Baylor College of Medicine